
ANRO Stock Forecast & Price Target
ANRO Analyst Ratings
Bulls say
Alto Neuroscience Inc has demonstrated significant advancements in its drug candidates, particularly with ALTO-207 (CTC-501), which has shown enhanced tolerability compared to pramipexole, allowing for higher dosing and a faster titration regimen that may improve treatment outcomes for depressive symptoms. The company's revenue for FY24 reached $1.08 billion, marking an approximate 60% increase from the previous fiscal year, highlighting robust financial growth. Additionally, the development of a new transdermal formulation for ALTO-101 has resulted in a better safety profile and favorable pharmacokinetics, supporting ongoing clinical trials and reinforcing confidence in Alto's innovative approach to precision psychiatry.
Bears say
Alto Neuroscience Inc's stock has experienced significant downward pressure following the failure of its lead asset, ALTO-100, in a Phase 2b study for major depressive disorder (MDD) in October 2024, compounded by negative results from ALTO-300. The initial setback raises concerns about the company's direction, as patients with poor memory and cognition typically face greater treatment resistance and worse outcomes, highlighting the challenges in treating depression effectively. Additionally, the ongoing Phase 2b study in bipolar depression, which carries a low probability of success (POS), adds to the skepticism surrounding the viability of the company's clinical programs.
This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.
ANRO Analyst Forecast & Price Prediction
Start investing in ANRO
Order type
Buy in
Order amount
Est. shares
0 shares